India has bolstered its Pharmaceutical Manufacturing Linked Incentive (PLI) scheme to reduce reliance on Chinese imports. With an initial outlay of ₹6,940 crore, the government aims to strengthen the domestic drug manufacturing industry. The PLI schemes, running from 2022-2023 to 2028-29, cover various sectors, including medical devices, pharmaceuticals, and bulk drugs. Under the bulk drugs PLI scheme, 48 projects have been selected, facilitating the production of essential drug ingredients like penicillin G and clavulanic acid used in antibiotics. However, challenges persist as some drugs remain unviable despite the incentives offered, leading to concerns about Chinese dumping in the market. The industry is calling for further safeguards to protect against such practices and ensure sustainable growth.
Read more from livemint.com
